AXL-TBK1 driven nuclear AKT3 promotes metastasis
E. N. Arner, J. M. Westcott, S. Hinz, C. E. Tiron, M. Blo, A. Mai, R. Virtakoivu, N. Z. Phinney, S. Nord, K. Y. Aguilera, A. Rizvi, J. E. Toombs, T. Reese, V. Fey, D. Micklem, , R. A. Brekken
This study identifies AXL-TBK1-driven nuclear AKT3 as a driver of EMT and metastasis, showing that selective AKT3 inhibition reduces tumor progression in breast cancer.
bioRxiv · Jan 17, 2022 · PreprintCancer Biology